An exploratory pooled analysis indicates that the Lung Immune Prognostic Index score is associated with overall survival and progression-free survival in metastatic non-small-cell lung cancer patients receiving immune checkpoint inhibitors, targeted therapy, or cytotoxic chemotherapy.
Hurricane disasters significantly and adversely impact the overall survival of patients undergoing definitive radiotherapy for locally advanced non-small-cell lung cancer, study findings suggest.
Data from two phase II studies published in JAMA Oncology lend support to the sequential use of local ablative therapy and PD-1 blockade in patients with metastatic non-small-cell lung cancer.
Findings from an extended follow-up of the National Lung Screening Trial maintain that low-dose computed tomography screening significantly reduces risk for lung cancer death versus chest radiography screening among high-risk current and former smokers.
Single-agent vemurafenib has demonstrated promising antitumor activity against non-small-cell lung cancer harboring BRAF V600E mutations in the VE-BASKET trial.